Vice President, Head Business Development and Strategic Alliances
AIQ's TRAQinform IQ technologies quantifies and classifies lesion-specific treatment response and organ-specific toxicity from longitudinal imaging scans. It can deliver an early prediction of optimal/suboptimal responders to therapies allowing for optimal patient section and more efficient go/no-go clinical decisions. It also provides concordance between multiple imaging modalities and radiotracers. AIQ has the ONLY technology that can quantify and characterize treatment response for each individual lesion and organ system automatically.With this intelligence, AIQ software can make early predictions of treatment effectiveness and toxicity risk.Pharma and biotech companies are using AIQ's technology in early stage studies to better understand pharmacodynamic effects, toxicity risk, and mechanisms of resistance.